New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
08:17 EDTMRTXMirati Therapeutics price target raised to $27 from $20 at Brean Capital
Brean Capital raised its price target on Mirati Therapeutics as the company continues to move its pipeline forward, positive trials updates, and expectations for upfront payments and royalties from potential partnerships. Shares are Buy rated.
News For MRTX From The Last 14 Days
Check below for free stories on MRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2014
08:08 EDTMRTXMirati Therapeutics initiates Phase 1 study of MGCD516
Mirati Therapeutics announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer. MGCD516 is a Receptor Tyrosine Kinase inhibitor with molecular targets that act as critical genetic drivers of cancer progression. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected NSCLC and other solid tumor patient populations whose tumors have genetic alterations in targets potently inhibited by MGCD516 including Trk, RET and DDR.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use